ChemWerth Files its 500th Drug Master File with FDA

FOR IMMEDIATE RELEASE

July 15, 2020

 

ChemWerth Files its 500th Drug Master File with FDA

Woodbridge, Conn. – ChemWerth Inc., a leading supplier of generic Active Pharmaceutical Ingredients (APIs), filed a Drug Master File (DMF) with the Food and Drug Administration (FDA) for Clevidipine, making it the company’s 500th DMF in its history. ChemWerth filed its first DMF in 1987 and continues to rank among world leaders for DMFs available for reference.

 

The achievement of 500 DMFs represents ChemWerth’s staying power over 38 years, and is a testament to the company’s regulatory and compliance prowess. ChemWerth’s average review cycle for DMF filings is just 0.79 in comparison with the industry average of 2.5 cycles. The efficiency in review cycles enables ChemWerth to turn DMFs around quickly to provide customers with an early-to-market advantage, which can lead to significant market share and revenue opportunity.

 

“Speed to market is paramount to succeed in the pharmaceutical landscape. Our regulatory experience and expertise helps us get the filing right the first time with 44% of the filings accepted in the initial pass,” said Peter Werth, president and founder, ChemWerth. “Our best-in-class regulatory team is dedicated to delivering exceptional value for our customers.”

 

ChemWerth provides high-quality APIs to regulated markets worldwide. Unlike trader-brokers, ChemWerth is a full-service API supplier with capabilities to support both large and small finished dosage companies. Through exclusive development and partnerships with API manufacturers, the company has a proprietary product selection process and extensive product portfolio.

 

About ChemWerth Inc.: Founded in 1982, ChemWerth is a world leader in developing and supplying specialty generic Active Pharmaceutical Ingredients (APIs) for human and animal health markets worldwide. The company continues to rank among world leaders for DMFs available for reference. ChemWerth is the regulatory agent for 25-plus FDA-approved facilities in the United States, Europe, India and China. The company sells 100-plus products in 38 countries around the globe. For more information about the company, please visit www.chemwerth.com.

API industry is facing serious headwinds that require re-strategizing business models

peter-werthThis week, we bring you another interesting interview with Peter J. Werth, President and Chief Executive Officer of ChemWerth, a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company providing current Good Manufacturing Practices (cGMP) quality APIs to the regulated markets. Werth talks about how complexities have increased in the last one year wherein the conversation on compliance has evolved from strictly GMP processes to data integrity and now Environmental Health and Safety (EHS). With the US Food and Drug Administration (FDA) publishing research for free, it is also becoming harder for generic manufacturers to find new products. Moreover, increasing costs mandate that API manufacturers put more efforts in product development so that the time to approval is considerably reduced. In light of these new challenges, Werth discusses the high standards and goals being set by his organization.

Read the interview on pharmacompass.com

“FDA’s enforcement actions are putting the global pharmaceutical supply chain at risk”

peter-werthPeter J. Werth, President and Chief Executive Officer of ChemWerth, a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company providing current Good Manufacturing Practices (cGMP) quality APIs to the regulated markets, shares his view on how the government inspections have evolved over the past years. The effect of the recent US Food and Drug Administration (US FDA) inspections is putting the global pharmaceutical supply chain in real danger. Excerpts from the interview.

Read the interview on pharmacompass.com